Regional radiotherapy versus an axillary lymph node dissection after lumpectomy: a safe alternative for an axillary lymph node dissection in a clinically uninvolved axilla in breast cancer. A case control study with 10 years follow up

Patty H Spruit¹, Sabine Siesling², Marloes AG Elferink², Ernest JA Vonk¹ and Carel JM Hoekstra*¹

Address: ¹Radiotherapeutic Institute RISO, Deventer, The Netherlands and ²Comprehensive Cancer Centre Stedendriehoek Twente, Enschede, The Netherlands

Email: Patty H Spruit - p.spruit@risomail.nl; Sabine Siesling - s.siesling@ikst.nl; Marloes AG Elferink - m.elferink@ikst.nl; Ernest JA Vonk - e.vonk@risomail.nl; Carel JM Hoekstra* - c.hoekstra@risomail.nl

* Corresponding author

Abstract

Background: The standard treatment of the axilla in breast cancer used to be an axillary lymph node dissection. An axillary lymph node dissection is known to give substantial risks of morbidity. In recent years the sentinel node biopsy has become common practice. Future randomized study results will determine whether the expected decrease in morbidity can be proven.

Methods: Before the introduction of the sentinel node biopsy, we conducted a study in which 180 women of 50 years and older with T1/T2 cN0 breast cancer were treated with breast conserving therapy. Instead of an axillary lymph node dissection regional radiotherapy was given in combination with tamoxifen (RT-group). The study group was compared with 341 patients, with the same patient and tumour characteristics, treated with an axillary lymph node dissection (S-group).

Results: The treatment groups were comparable, except for age. The RT-group was significantly older than the S-group. The median follow up was 7.2 years. The regional relapse rates were low and equal in both treatment groups, 1.1% in RT-group versus 1.5% in S-group at 5 years. The overall survival was similar; the disease free survival was significant better in the RT-group.

Conclusion: Regional recurrence rates after regional radiotherapy are very low and equal to an axillary lymph node dissection.

Background

Before the introduction of the sentinel node biopsy, the standard treatment of the axilla in early stage breast cancer was an axillary lymph node dissection (ALND). An ALND results in a high risk of morbidity, while in 70% of the postmenopausal patients with early stage breast cancer an ALND would be unnecessary because of the absence of lymph node metastases [1-4]. Lymph oedema of the arm (2–28%) [4-6] and shoulder function impairment (3–
An alternative to an ALND is primary regional radiotherapy. This is expected to give less morbidity: arm oedema to a lesser extent (0–9%) and shoulder function impairment (0–1%) [4,9] are noted. Dysesthesia and pain are neither mentioned nor expected.

It is always a challenge to find alternative treatments leading to less complaints but this may not lead to major changes in tumour control and survival rates.

This study was initiated under the assumption that the control rates and survival after regional radiotherapy instead of an ALND in breast cancer patients of 50 years and older, are comparable while the morbidity is less, resulting in a better quality of life.

**Methods**

**Patient population**

Over the period 1991–2000 women aged 50 years and older with T1 or T2 breast cancer, with clinically negative axilla (cN = 0, assessed by physical examination) diagnosed in the Deventer Hospital were treated with axillary radiotherapy instead of an ALND. If the patients preferred the standard treatment (ALND), this was given. To compare the study group, a control group was compiled from all patients treated in the Gelre Hospitals Apeldoorn, over the same period with the same patient and tumour characteristics, and the patients from the Deventer Hospital not treated within the study protocol. Both patient groups were retrieved by using the regional cancer registry of the Comprehensive Cancer Centre Stedendriehtoek Twente. In this population based cancer registry all newly diagnosed malignancies are registered. All charts were reviewed by the radiation oncologists of our department, concerning patient and tumour characteristics, recurrences and survival. All TNM stages were converted into the latest version (sixth edition) [10].

**Treatment**

Patients treated with lumpectomy without an ALND (RT-group), were irradiated on the breast, the axillary, supra- and infraclavicular lymph nodes and the ipsilateral internal mammary chain. The radiotherapy started within 6 weeks after surgery. All patients were irradiated on the breast with 2 tangential fields on a linear accelerator with 6 or 10 MV photon beams. Total dose to the entire breast was 50 Gy, in 2 Gy fractions, followed by a boost at the tumour bed of 14 Gy. Irradiation of the axilla was performed with the so-called McWirtsher technique to prevent overlap with the tangential fields of the breast: supraclavicular and axillary with two ventrodorsal opposed half-beam fields, 6 MV photon beams, the medial part only from ventral, specified at 3 cm. The internal mammary chain was irradiated with a single ventrodorsal beam, 26 Gy with a 6 MV photon energy beam followed by 24 Gy 12 MeV electrons. In individual cases the internal mammary chain was not irradiated as a result of the physician’s opinion based on age of the patient, tumour characteristics (like size) or localisation of the tumour (lateral part of the breast).

Although the receptor status was unknown in most patients, adjuvant hormonal treatment, i.e. tamoxifen 20 mg a day, was given to all patients. The duration of the hormonal treatment was at least 2 years. Evolving data during the period of the current study showed the possible benefits of extended hormonal therapy use, therefore some patients were treated for 5 years.

Patients who underwent a lumpectomy and an ALND, a level 1 and 2 resection, (S-group) were irradiated on the breast, with 2 tangential fields as described above. Depending on the pathological findings of the tumour and the lymph nodes, regional radiotherapy and adjuvant therapy (hormonal and/or chemotherapy) were given according to the National guidelines. These patients were irradiated on the internal mammary lymph nodes in case of a positive axilla and/or a tumour in the medial part of the breast. When the EORTC trial investigating the role of irradiation of the internal mammary lymph nodes [11] was initiated, the patients were only irradiated on this chain within the participation of this trial (16 patients of the S-group participated in this trial).

**Follow-up**

For all selected patients the follow-up was completed by performing a chart review.

All patients were followed every 3 months in the first year, every six months from the second to the tenth year, by the radiation oncologist alternated with the surgeon. With every visit the patient was checked for locoregional recurrence, signals for distant metastases and side effects. Unfortunately no validated morbidity lists were used so a reliable overview of differences in morbidity can not be given. Every year a mammography was made. After 10 years of disease free follow-up, the patients were discharged.

If information about follow-up was lacking in the patient file, general practitioners were contacted.

**Statistical analysis**

Differences between the two treatment groups were determined using a chi-squared test. Disease free survival and overall survival were calculated, using multivariate Cox regression in SPSS (Statistical Package for Social Sciences).
In the disease free survival analysis, the endpoint was the first local recurrence, regional recurrence or metastasis. All deaths, irrespective of cause of death, were taken as endpoint in the overall survival. Patients without an endpoint were censored at the end of their follow-up in the survival analysis. The effect of the treatment (RT or surgery) was adjusted for the variables tumour stage pT, age and irradiation of the internal mammary chain. P-value <0.05 was considered to be statistical significant.

**Results**

In total 524 patients were selected from the cancer registry, 3 patients were lost to follow up. Of the 521 patients evaluated, 180 were treated within the RT-group protocol. Three hundred and forty-one patients were treated with an ALND. In table 1 characteristics of both patient groups are shown. The difference in age between both groups was significant (p < 0.001). The median follow-up was 7.2 years (mean 7.7 years). The treatment characteristics are shown in table 2.

After 5 years, the number of regional recurrences was very low and no differences were found between the 2 treatment groups, two (1.1%) in the RT-group and five (1.5%) in the S-group. In the RT-group one regional recurrence was found in the supravacular region and the other combined infraclavicular/axillar. In the S-group they were located in the supravacular region and the axilla in 2 cases each and one combined supravacular/axillar. After dissemination research two of these patients (1 in each group) showed distant metastasis.

The local control rates were better in the RT-group, with local recurrence rate of 2.2% and 3.5% at 5 years in the RT and the S-group respectively. Distant failures occurred less often in the RT-group: 6.7% vs. 10.3%.

The overall survival (OS) was similar in both groups. The 5 and 10-year OS rates in the RT-group were 92% and 80%, in the S group these were 90% and 75% respectively, figure 1.

**Table 1: patient and tumour characteristics**

|                  | RT-group | S-group |
|------------------|----------|---------|
| Number of patients | 180      | 341     |
| Age, years*      | 67       | 61      |
| T stages (%)     |          |         |
| pT1              | 67.8     | 79.5    |
| pT2              | 32.2     | 20.5    |
| N stages (%)     |          |         |
| PNx              | 100      | -       |
| pN0              | -        | 76.8    |
| pN1              | -        | 22.9    |
| pN2              | -        | 0.3     |

*P < 0.05

The disease free survival (DFS) was better in the RT-group, with a Hazard Ratio of 0.4 (95% CI: 0.3 – 0.8, p = 0.003) in the univariate analysis and 0.4 (95% CI: 0.2 – 0.7, p = 0.001) in the multivariate analysis corrected for age, stage and radiotherapy of the internal mammary chain, table 3; figure 2.

**Discussion**

The main issue of this article is the regional control in patients of 50 years and older with T1–2 cN0 breast cancer treated with breast conserving therapy and regional radiotherapy compared to an axillary lymph node dissection. The low regional recurrence rates in our study show that RT is a safe alternative for an ALND.

It is hard to draw firm conclusions in this non-randomized setting, where selection can not be ruled out, but some comparisons can be made.

Five studies with primary axillary radiotherapy have been published before [1,9,12-14]. Despite the somewhat dif-
ferent patient characteristics and adjuvant treatment they all confirm low regional recurrence rates. Compared to these articles we have a slightly better DFS, and a higher hormonal therapy usage, 98.9% vs. 2.4% - 71% [9,12,13]. They also conclude that RT equals an ALND with regard to survival, table 4.

The disease free survival was significantly better in the RT-group, in the univariate as well as the multivariate analysis (p < 0.05). A few explanations are possible.

The number of patients irradiated on the internal mammary lymph nodes was significantly higher in the RT-group. We cannot tell what the influence of this on the DFS has been. Probably the results of the EORTC trial, [11] will clarify this.

Locoregional radiotherapy, which was given to all the patients in the RT-group, gives a better locoregional control and even a better survival in high risk postmenopausal breast cancer patients [15]. Recently Overgaard described in a subanalysis of the DBCG 82 b&c trial that intermediate risk patients (1–3 positive lymph nodes) benefit from locoregional radiotherapy, not only for locoregional control but also for survival [16]. It can be assumed that the percentage of positive axillary lymph nodes would be similar in both groups. Therefore it is very well possible that the RT-group contains patients (23%) that would have been classified as intermediate risk breast cancer. Whether this explains the better DFS in our study group is hard to tell. In October 2006 an EORTC study started to give answers on that matter too (SUPREMO) [17].

On the other hand, there are some reports showing that no treatment of the axilla at all in early breast cancer, is an option too [18-20]. These studies treated patients with higher age (>70 yr) and/or smaller tumours (< 1.2 cm) than we did. The tamoxifen usage was at least 90% in all of them. The axillary recurrences rates in these studies varied from 1,5% to 5.4%.

Tamoxifen was prescribed to all patients in the RT-group. Literature shows that tamoxifen not only diminishes the amount of distant failures but the local recurrences as well [21]. It could be that this explains the differences in local and distant failures between our two groups.

As mentioned before no reliable evaluation of the complications like lymph oedema or shoulder impairment could be made.

The last few years the sentinel node procedure seems to have proven its value. In the Netherlands staging of the axilla in low risk breast cancer is routinely performed by the SNP. Because the sentinel node biopsy is less invasive, it gives less morbidity than an ALND. If the sentinel node is tumour negative no further treatment of the axilla is

| Table 3: results of univariate and multivariate analysis of disease free survival |
|-----------------------------------------------|
| Factor                                      | Univariate | Multivariate |
|                                              | No   | HR | 95% CI | No   | HR | 95% CI |
| S-group                                      | 341  | 1  | Reference | 1  | Reference |
| RT-group                                    | 180  | 0.4 | 0.3–0.8 | 0.4 | 0.2–0.7 |
| RT internal mammary chain                   | Yes  | 220 | 1 | Reference | 1 | Reference |
|                                              | No   | 301 | 1.0 | 0.7–1.6 | 0.7 | 0.4–1.1 |
|                                              | pT1  | 393 | 1 | Reference | 1 | Reference |
|                                              | pT2  | 128 | 1.6 | 1.0–2.6 | 1.8 | 1.1–2.8 |
|                                              | Age  | 521 | 1.0 | 0.9–1.0 | 1.0 | 0.9–1.0 |

![Image](image-url)  
**Figure 2** Disease free survival by treatment, with numbers of patients at risk at 10 years.
necessary. If the sentinel node shows metastases the axilla needs to be treated, either with an ALND or with radiotherapy [22]. The combination of a SNP and axillary radiotherapy will probably not lead to substantial morbidity, as we see after an ALND in combination with radiotherapy of the axilla.

It is to be expected that in the future an ALND will be of lesser importance in the staging of breast carcinoma, especially with the upcoming techniques like Her2-neu expression and genomics. Together with the findings in the sentinel node the indication for adjuvant therapy will be determined. A randomized multicentre trial is investigating the difference between an ALND and axillary, supra- and infraclaviculay radiotherapy in patients with a positive sentinel node biopsy (AMAROS trial) [23].

Conclusion
Regional recurrence rates after regional radiotherapy are very low and can safely replace surgery in a clinically negative axilla.

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
PS: collected data, wrote the article
SS: conducted data evaluation, statistical analysis, critical review of the manuscript
ME: conducted data evaluation, statistical analysis
EV: collected data, critical review of the manuscript.

CH: designed the RT-group treatment protocol, collected data, critical review of the manuscript.

All authors read and approved the final manuscript.

Acknowledgements
Our special thanks go to the medical staff of RISO for scoring all the charts and to Anke Schellekens our data manager.

References
1. Chua B, Ung O, Boyages J: Treatment of the axilla in early breast cancer: past, present and future. ANZ J Surg 2001, 71:729-736.
2. Fisher B, Wolmark N, Bauer M, Redmond C, Gehbardt M: The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981, 152:765-772.
3. Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, Deutsch M, Montague E, Margolese R, Foster R. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985, 312:674-681.
4. Pierquin B, Mazeron JJ, Glaubiger D: Conservative treatment of breast cancer in Europe: report of the Groupe Europeen de Curietherapie. Radiother Oncol 1986, 6:187-198.
5. Ozaslan C, Kuru B: Lymphedema after treatment of breast cancer. Am J Surg 2004, 187:69-72.
6. Schijven MP, Vingerhoets AJ, Rutten HJ, Nieuwenhuijzen GA, Roumen RM, van Bussel ME, Voogd AC: Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy. Eur J Surg Oncol 2003, 29:341-350.
7. Silberman AW, McVay C, Cohen JS, Altura JF, Brackett S, Sarna GP, Palmer D, Ko A, Memsic L: Comparative morbidity of axillary lymph node dissection and the sentinel lymph node technique: implications for patients with breast cancer. Ann Surg 2004, 240:1-6.
8. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiannou C, Horgan K, Hundred N, Monypenny I, England D, Sibbering M, Abdullah IT, Barr L, Chetty U, Simms DH, Fleissig A, Clarke D, Ell PJ: Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006, 98:599-609.
9. Hoebers FJ, Borger JH, Hart AA, Petersen JL, Th EJ, Labbesque JY: Primary axillary radiotherapy as axillary treatment in breast-conserving therapy for patients with breast carcinoma and...
clinically negative axillary lymph nodes. *Cancer* 2000, 88:1633-1642.

10. LH S, Ch W: International Union against Cancer (UICC): TNM Classification of malignant tumours. Sixth edition. New York, Wiley-Liss; 2002.

11. Phase III randomized trial investigating the role of internal mammary and medial supraclavicular (IM-MS) lymph node chain irradiation in stage I-III breast cancer (Joint study of the EORTC Radiotherapy Cooperative Group and the EORTC Breast Cancer Cooperative Group EORTC 22922/10925). 1996.

12. Louis-Sylvestre C, Clough K, Asselain B, Vilcoq JR, Salmon RJ, Campana F, Fourquet A: Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. *J Clin Oncol* 2004, 22:97-101.

13. Wong JS, Recht A, Beard Cj, Busse PM, Cady B, Chaffey JT, Come S, Fam S, Kaelin C, Lingos T, Nixon AJ, Shulman LN, Troyan S, Silver B, Hentsch S: Treatment outcome after tangential radiotherapy without axillary dissection in patients with early-stage breast cancer and clinically negative axillary nodes. *Int J Radiat Oncol Biol Phys* 1997, 39:915-920.

14. Wazer DE, Erban JK, Robert NJ, Smith TJ, Marchant DJ, Schmid C, DiPersio F, Schmidt-Ullrich R: Breast conservation in elderly women for clinically negative axillary lymph node without axillary dissection. *Cancer* 1994, 74:878-883.

15. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Anderson M, Kamby C, Kjaer M, Gadeberg CC, Rasmussen BB, Blichert-Toft M: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. *Lancet* 1999, 353:1641-1648.

16. Overgaard M, Nielsen HM, Overgaard J: Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. *Radiother Oncol* 2007, 82:247-253.

17. Selective Use of Postoperative Radiotherapy After Mastectomy SUPREMO. EORTC 22051. 2006.

18. Martelli G, Miceli R, De PG, Coradini D, Salvadori B, Zucali R, Galante E, Marubini E: Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla? *Cancer* 2003, 97:1156-1163.

19. Martelli G, Boracchi P, De PM, Pilotti S, Oriana S, Zucali R, Daidone MG, De PG: A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up. *Ann Surg* 2005, 242:1-6.

20. Veronesi U, Orecchia R, Zurrida V, Galimberti V, Luini A, Veronesi P, Gatti G, D’Aiuto G, Cataliotti L, Paolucci R, Piccolo P, Massaoli N, Sismondi P, Rulli A, Lo SF, Recalcati A, Terrile D, Acerbi A, Rotmensz N, Maisonneuve P: Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. *Ann Oncol* 2005, 16:383-388.

21. Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Neubtt L, Paik S, Pisansky TM, Wolmark N: Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. *J Clin Oncol* 2002, 20:4141-4149.

22. Sandrucki S, Casalegno PS, Pernicale P, Mistrangelo M, Bondalieri E, Bertoglio S: Sentinel lymph node mapping and biopsy for breast cancer: a review of the literature relative to 4791 procedures. *Tumori* 1999, 85:425-434.

23. After Mapping of the Axilla:Radiotherapy Or Surgery AMAROS. EORTC10981/22023. 2001.